Main Article Content
Introduction: Information on microbiological and susceptibility profiles of Monoglian bacterial isolates is scarce. Resistance profiles, patient demographics and microbiological work-up of gram positive isolates were analyzed in order to develop infection control activities and policies at the National Center for Maternity and Children’s Health (NCMCH) in Ulaanbataar, Mongolia.
Methods: All gram positive isolates of specimens submitted to the microbiology laboratory at NCMCH between January 2014 and August 2017 were included. Data collected included demographic data, specimen type, in-/outpatient status, hospital ward of sample origin, and antimicrobial susceptibility testing profile. Susceptibility testing was performed by trained microbiologists at the NCMCH microbiology laboratory. T-test, Mann-Whitney, Chi-square and Fisher exact tests were used as appropriate.
Results: Of 11,889 isolates, 4012 (33.7%) were gram positive, with most identified as S. aureus (62.6%, n=2512). Rates of methicillin resistance (MRSA) remained stable at a quarter, but was significantly higher among inpatients (inpatients: 630/2002, 31.5%; outpatients 67/290, 23.1%; p?0.05) and sterile site isolates (sterile: 83/171, 48.5%; non-sterile: 416/1678, 24.8%; p?0.01). The vast majority of S. pneumoniae isolates (12/14; 85%) was found to be penicillin resistant by oxacillin disk diffusion. While identification of Group B streptococci was rare (n=137) due to of lack of diagnostic measures available, the number of enterococcal isolates identified increased signifi-cantly due to implementation of improved microbiological work-up (2015: n=7; 2016: n=26; 2017: n=83).
Conclusion: Compared with published studies from neighboring nations, the rates of antimicrobial resistance among gram positive isolates at NCMCH, particularly with respect to S. aureus and S. pneumoniae, were much higher. Further improvement of microbiological diagnostics and collabo-ration of stakeholders is required to address the pressing infection control and stewardship issues and to ensure reliable identification of relevant pathogens in Mongolia.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Revised 7/16/2018. Revision Description: Removed outdated link.
David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616-87.
Review on Antimicrobial Resistance. Antimicrobial Resistance: Final report and recommen-dations. 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Wellcome Trust. Jim O’Neill (chair). Accessed on 14 Sepetmeber, 2019
Global action plan for antimicrobial resistance. World Health Organization. ISBN 978 92 4 150976 3. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf. Accessed on 14 Sepetmeber, 2019
Batsukh Z, Tsolmon T, Otgonbaatar D, Undraa B, Dolgorkhand A, Ochirpurev A. One Health in Mongolia. 2016. Pages 123-137. in Mackenzie JS, Jeggo M, Daszak P, Richt JA ed-itors. One Health: The Human-Animal-Environment Interfaces in Emerging Infectious Diseases.
National Multi-sectorial Action Plan on Combating Antimicrobial Resistance, 2017-2020. http://www.wpro.who.int/mongolia/en/. Accessed on 14 Sepetmeber, 2019
Versporten A, Zarb P, Caniaux I, et al. Antimicrobial consumption and resistance in adult hos-pital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018; 6(6):e619-e629
van den Hof S, Woudt S, Monen J, et al. Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CESAR). Annual report 2018. ISBN 978 92 890 5386 0
Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream10665/112642/1/9789241564748_eng.pdf. Accessed on 14 Sepetmeber, 2019
Lee Y, Wakabayashi M. Key informant interview on antimicrobial resistance (AMR) in some countries in the Western Pacific region. Global Health. 2013; 26(9):34.
National Statistics Office of Mongolia. Social and economic situation of Mongolia (October 2018). http://www.en.nso.mn/content/293. Accessed on 14 Sepetmeber, 2019
UNICEF Multiple Indicative Cluster Surveys, Mongolia. http://mics.unicef.org/surveys. Accessed on 14 Sepetmeber, 2019
Togoobaatar G, Ikeda N, Ali M, et al. Survey of non-prescribed use of antibiotics for chil-dren in an urban community in Mongolia. Bull World Health Organ. 2010;88(12):930-6
WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. World Health Organization 2018. ISBN 978-92-4-151488-0
Viderman D, Brotfain E, Khamzina Y, Kapanova G, Zhumadilov A, Poddighe D. Bacterial Resistance in the Intensive Care Unit of developing countries: report from a tertiary hospital in Kazakhstan. J Glob Antimicrob Resist. 2018(15): S2213.
Shonkuuz, E. et al. Department of Informatics and Statistics, National Center for Maternal and Child Health, 2017.
WHONET. http://www.whonet.org. Accessed on 14 Sepetmeber, 2019
CLSI Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI sup-plement M100S. Wayne PA. Clinical and Laboratory Standards Institute, 2016.
CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Ap-proved Guideline, 4th ed. CLSI document M39-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
Laboratory Detection of: Oxacillin/Methicillin-resistant Staphylococcus aureus. https://www.cdc.gov/hai/settings/lab/lab_mrsa.html. Accessed on 14 Sepetmeber, 2019
Giske CG, Martinez-Martinez L, Cantón R. EUCAST subcommittee for detection of resis-tance mechanisms and specific resistances of clinical and/or epidemiological importance: 2013. version 1.0. http://www.amcli.it/wp-content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf. Accessed on 14 Sepetmeber, 2019
Dien Bard J, Hindler JA, Gold HS, Limbago B. Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaro-line. Clin Infect Dis. 2014; 58(9): 1287–1296.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Sus-ceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16. ISBN 1-56238-588-7. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.
Walters M, Lonsway D, Rasheed K, et al. Investigation and Control of Vancomycin-resistant Staphylococcus aureus: A Guide for Health Departments and Infection Control Personnel. Atlanta, GA 2015. http://www.cdc.gov/hai/pdfs/VRSA-Investigation-Guide-05_12_2015.pdf. Accessed on 14 Sepetmeber, 2019
Swenson J. M., Hill B. C., Thornsberry C. Screening pneumococci for penicillin resistance. J. Clin. Microbiol. 1986; 24:749–752.
Choi S, Chung JW, Sung H, et al. Impact of Penicillin Nonsusceptibility on Clinical Out-comes of Patients with Nonmeningeal Streptococcus pneumoniae Bacteremia in the Era of the 2008 Clinical and Laboratory Standards Institute Penicillin Breakpoints. Antimicrob Agents Chemother. 2012; 56(9): 4650–4655.
Mayanskiy N, Alyabieva N, Ponomarenko O et al. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis. 2014; 20:58-62.
Belyaev I, Belyaev A. Sensitivity study of antimicrobial pneumococci in central Kazakhstan. Georgian Med News. 2017; (262):101-106.
Sundaram N, Chen C, Yoong J, et al. Cost-effectiveness of 13-valent pneumococcal conju-gate vaccination in Mongolia. Vaccine. 2017; 35(7):1055–1063.
Longtin J, Vermeiren C, Shahinas D, et al. Novel mutations in a patient isolate of Strepto-coccus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppres-sive therapy. Antimicrob Agents Chemother 2011;55:2983–2985.
Seki T, Kimura K, Reid ME, et al. High isolation rate of MDR group B streptococci with re-duced penicillin susceptibility in Japan. J Antimicrob Chemother 2015;70:2725–2728.
Nair R, Hanson BM, Kondratowicz K, et al. Antimicrobial resistance and molecular epidemi-ology of Staphylococcus aureus from Ulaanbaatar, Mongolia. PeerJ 2013;1:e176
Khudaibergenova MS. Antimicrobial use at a multi-disciplinary hospital. Int J Risk Saf Med. 2015;27 Suppl 1:S13-4.
Panesso D, Planet PJ, Diaz L, et al. Methicillin-Susceptible, Vancomycin-Resistant Staphylo-coccus aureus, Brazil. Emerg Infect Dis. 2015 Oct; 21(10): 1844–1848.